Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
Discov Med
; 21(116): 293-303, 2016 04.
Article
en En
| MEDLINE
| ID: mdl-27232515
ABSTRACT
Uterine serous carcinoma (USC) is a rare but aggressive subtype of endometrial cancer. Although it represents only 10% of all endometrial cancer cases, USC accounts for up to 40% of all endometrial cancer-related recurrences and subsequent deaths. With such a dismal prognosis, there is an expanding role for novel targeted approaches in the treatment of USC. Recent whole-exome sequencing studies have demonstrated gain of function of the HER2/NEU gene, as well as driver mutations in the PIK3CA/AKT/mTOR and cyclin E/FBXW7 oncogenic pathways in a large number of USCs. The results emphasize the relevance of these novel therapeutic targets for biologic therapy of USC, which will be reviewed in this article.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Uterinas
/
Transducción de Señal
/
Neoplasias Endometriales
/
Cistadenocarcinoma Seroso
/
Terapia Molecular Dirigida
/
Recurrencia Local de Neoplasia
/
Antineoplásicos
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
Discov Med
Año:
2016
Tipo del documento:
Article
País de afiliación:
Estados Unidos